Literature DB >> 8366226

Selective digestive decontamination by erythromycin-base in a polyvalent intensive care unit.

C L de Champs1, D P Guelon, R M Garnier, M C Poupart, O Y Mansoor, F L Dissait, J L Sirot.   

Abstract

OBJECTIVE: To study the effect of selective digestive tract decontamination by erythromycin-base on the incidence of carriage and infection with MR Enterobacteriaceae producing an extended spectrum beta-lactamase (ESB).
DESIGN: After a 10-week prospective survey to ascertain the baseline incidence in two bays (1 and 3) of the same ICU, bay 1 was compared with bay 3 during a further survey of 6 months. The patients in bay 1 received erythromycin-base.
SETTING: Two non-contiguous bays, 1 and 3, of 4 beds, in the same polyvalent ICU of a university hospital. PATIENT: Consecutive patients with unit stay longer than 2 days; 34 patients were included during the control period, 43 in bay 1 (decontamination) and 46 in bay 3 (control) during the trial period. INTERVENTION: Erythromycin-base, 1 g t.i.d. in powder form administered by gastric tube to patients in bay 1 from admission to discharge. MEASUREMENTS AND
RESULTS: Digestive tract carriage was monitored by cultures of gastric and rectal swab specimens, sampled twice a week. Enterobacteriaceae were isolated on Drigalski agar with incorporated ceftazidime (4 mg/l). In bay 1 there was a decrease in ESB producing Enterobacteriaceae (23% vs 10%, p = 0.0004) from rectal swab, especially in K. pneumoniae (15% vs 2%, p = 10(-5)), during the decontamination period in comparison to the control period. During the trial period the only differences observed between bays 1 and 3 were in the gastric samples: K. pneumoniae were less often isolated in bay 1 than in bay 3 (0% vs 3%, p = 0.03). Intestinal carriage with multiresistant Enterobacteriaceae occurred in 28% patients in bay 1 and 30% patients in bay 3 during the trial period (p = 0.79). Erythromycin-base did not delay the carriage by patients in bay 1 (log rank test p = 0.42).
CONCLUSION: Erythromycin-base was not effective in preventing digestive tract carriage due to Enterobacteriaceae resistant to third generation cephalosporin by production of chromosomal cephalosporinase. The decrease in isolates containing K. pneumoniae in bay 1 cannot be definitively attributed to erythromycin-base, since the number of this species in bay 3 was low.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366226     DOI: 10.1007/bf01694769

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  22 in total

1.  SDD and the novel extended-broad-spectrum beta-lactamases.

Authors:  W R Heizmann
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

2.  Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C de Champs; D Guelon; D Joyon; D Sirot; M Chanal; J Sirot
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

3.  Preoperative bowel preparation. Erythromycin base serum and fecal levels following oral administration.

Authors:  R L Nichols; R E Condon; A R DiSanto
Journal:  Arch Surg       Date:  1977-12

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 5.  Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care.

Authors:  I M Ledingham; S R Alcock; A T Eastaway; J C McDonald; I C McKay; G Ramsay
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

6.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

7.  Susceptibility of "enterobacteria" to penicillins, cephalosporins, lincomycins, erythromycin, and rifampin.

Authors:  M Finland; C Garner; C Wilcox; L D Sabath
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

8.  Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital.

Authors:  C de Champs; D Sirot; C Chanal; M C Poupart; M P Dumas; J Sirot
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

9.  A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection.

Authors:  R Winter; H Humphreys; A Pick; A P MacGowan; S M Willatts; D C Speller
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

10.  Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit.

Authors:  C Brun-Buisson; P Legrand; A Rauss; C Richard; F Montravers; M Besbes; J L Meakins; C J Soussy; F Lemaire
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

View more
  3 in total

Review 1.  Selective decontamination of the digestive tract: 13 years on, what it is and what it is not.

Authors:  D Baxby; H K van Saene; C P Stoutenbeek; D F Zandstra
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

2.  Reply to "selective digestive tract decontamination and spread of colistin resistance: antibiotic prophylaxis is not a substitute for hygiene".

Authors:  Teysir Halaby; Nashwan Al Naiemi; Christina M J E Vandenbroucke-Grauls
Journal:  Antimicrob Agents Chemother       Date:  2014-06       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.